AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) Short Interest Update

AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) saw a significant decrease in short interest in the month of June. As of June 15th, there was short interest totaling 3,204,092 shares, a decrease of 54.3% from the May 31st total of 7,013,343 shares. Approximately 22.0% of the company’s shares are short sold. Based on an average daily volume of 51,555,532 shares, the short-interest ratio is presently 0.1 days.

Analyst Ratings Changes

Separately, Ascendiant Capital Markets reduced their price target on shares of AIM ImmunoTech from $10.00 to $9.00 and set a “buy” rating on the stock in a research report on Monday, June 1st. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has issued a Hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $9.00.

Institutional Trading of AIM ImmunoTech

Several hedge funds have recently added to or reduced their stakes in the company. DRW Securities LLC lifted its stake in AIM ImmunoTech by 60.6% in the fourth quarter. DRW Securities LLC now owns 69,545 shares of the company’s stock worth $79,000 after acquiring an additional 26,254 shares during the last quarter. Sabby Management LLC acquired a new position in AIM ImmunoTech during the 3rd quarter worth approximately $79,000. Finally, Corient Private Wealth LLC purchased a new stake in shares of AIM ImmunoTech in the 2nd quarter valued at approximately $87,000. Institutional investors and hedge funds own 12.02% of the company’s stock.

AIM ImmunoTech Stock Up 4.2%

Shares of NYSEAMERICAN AIM traded up $0.01 during mid-day trading on Wednesday, hitting $0.30. The company had a trading volume of 831,291 shares, compared to its average volume of 16,151,601. The company has a market capitalization of $4.31 million, a PE ratio of -0.05 and a beta of 1.18. The business’s 50-day simple moving average is $0.43 and its 200 day simple moving average is $0.80. AIM ImmunoTech has a 1-year low of $0.21 and a 1-year high of $20.35. The company has a debt-to-equity ratio of 0.10, a current ratio of 1.01 and a quick ratio of 1.01.

AIM ImmunoTech (NYSEAMERICAN:AIM) last issued its quarterly earnings results on Friday, May 15th. The company reported ($0.69) earnings per share for the quarter. The business had revenue of $0.02 million during the quarter. On average, analysts predict that AIM ImmunoTech will post -0.63 earnings per share for the current year.

AIM ImmunoTech Company Profile

AIM ImmunoTech is a clinical-stage biotechnology company focused on the development and commercialization of immune-modulating therapies for the treatment of viral infections and cancer. The company’s lead product candidate, Ampligen (rintatolimod), is a proprietary toll-like receptor 3 (TLR3) agonist that aims to enhance the body’s innate immune response. AIM ImmunoTech’s research and development efforts center on demonstrating the safety and efficacy of Ampligen as both a standalone therapy and in combination with other treatments.

In addition to its oncology and antiviral programs, the company is advancing clinical trials of Ampligen in patients with chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) and exploring potential applications for emerging viral threats.